Intrauterine Device Use and Risk of Ovarian Cancer: Results from the New England Case-Control Study and Nurses' Health Studies

Overview

Journal Int J Cancer

Specialty Oncology

Date 2021 Feb 26

PMID 33634849

Citations 3

Authors

Jiaxi Yang

Naoko Sasamoto

Ana Babic

Allison F Vitonis

Mary K Townsend

Linda Titus

Daniel W Cramer

Shelley S Tworoger

Kathryn L Terry

Affiliations

Soon will be listed here.

Abstract

Results of studies assessing intrauterine device (IUD) use and ovarian cancer risk are inconsistent. We examined the association between IUD use, including duration, type and timing of use, and ovarian cancer risk using three population-based studies. Data from the New England Case-Control Study (NEC) and two prospective cohort studies, the Nurses' Health Studies (NHS/NHSII), were included in the analysis. Information on IUD use was collected by in-person interview in NEC and by biennial questionnaire in NHS/NHSII. We used unconditional logistic regression to calculate odds ratios (OR) and 95% confidence intervals (CI) in NEC and Cox regression to calculate hazard ratios (HR) and 95% CI in NHS/NHSII. We used meta-analysis to combine the NEC and the pooled NHS/NHSII results. Overall, IUD use was not associated with epithelial ovarian cancer risk (OR = 0.96, 95% CI: 0.81-1.14 in NEC; HR = 0.89, 95% CI: 0.69-1.15 in NHS/NHSII; combined RR = 0.94, 95% CI: 0.81-1.08). Among IUD users, older age at first use was associated with increased ovarian cancer risk (P-trend = .03). We did not observe significant associations by IUD type or duration of use. In conclusion, IUD use was not associated with ovarian cancer risk in our study.

Citing Articles

Incessant ovulation: a review of its importance in predicting cancer risk.

Cramer D Front Oncol. 2023; 13:1240309.

PMID: 37869082 PMC: 10588628. DOI: 10.3389/fonc.2023.1240309.

Reevaluating the Role of Progesterone in Ovarian Cancer: Is Progesterone Always Protective?.

Mauro L, Spartz A, Austin J, Lange C Endocr Rev. 2023; 44(6):1029-1046.

PMID: 37261958 PMC: 11048595. DOI: 10.1210/endrev/bnad018.

Beyond the pill: contraception and the prevention of hereditary ovarian cancer.

Xia Y, Kotsopoulos J Hered Cancer Clin Pract. 2022; 20(1):21.

PMID: 35668475 PMC: 9169328. DOI: 10.1186/s13053-022-00227-z.

References

Modugno F, Goughnour S, Wallack D, Edwards R, Odunsi K, Kelley J . Breastfeeding factors and risk of epithelial ovarian cancer. Gynecol Oncol. 2019; 153(1):116-122. PMC: 6558958. DOI: 10.1016/j.ygyno.2019.01.017. View

Ness R, Grisso J, Vergona R, Klapper J, Morgan M, WHEELER J . Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer. Epidemiology. 2001; 12(3):307-12. DOI: 10.1097/00001648-200105000-00010. View

MacIsaac L, Espey E . Intrauterine contraception: the pendulum swings back. Obstet Gynecol Clin North Am. 2007; 34(1):91-111, ix. DOI: 10.1016/j.ogc.2007.02.004. View

Callahan R, Kopf G, Strauss 3rd J, Tworoger S . Tubal contraception and ovarian cancer risk: a global view. Contraception. 2016; 95(3):223-226. DOI: 10.1016/j.contraception.2016.09.004. View

Le D, Kubo T, Fujino Y, Sokal D, Vach T, Pham T . Reproductive factors in relation to ovarian cancer: a case-control study in Northern Vietnam. Contraception. 2012; 86(5):494-9. DOI: 10.1016/j.contraception.2012.02.019. View

Babic A, Sasamoto N, Rosner B, Tworoger S, Jordan S, Risch H . Association Between Breastfeeding and Ovarian Cancer Risk. JAMA Oncol. 2020; 6(6):e200421. PMC: 7118668. DOI: 10.1001/jamaoncol.2020.0421. View

La Vecchia C . Oral contraceptives and ovarian cancer: an update, 1998-2004. Eur J Cancer Prev. 2006; 15(2):117-24. DOI: 10.1097/01.cej.0000179274.24200.9d. View

Dorjgochoo T, Shu X, Li H, Qian H, Yang G, Cai H . Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer. 2009; 124(10):2442-9. PMC: 2666967. DOI: 10.1002/ijc.24232. View

Cramer D, Vitonis A, Terry K, Welch W, Titus L . The Association Between Talc Use and Ovarian Cancer: A Retrospective Case-Control Study in Two US States. Epidemiology. 2015; 27(3):334-46. PMC: 4820665. DOI: 10.1097/EDE.0000000000000434. View

10.

Trussell J, Lalla A, Doan Q, Reyes E, Pinto L, Gricar J . Cost effectiveness of contraceptives in the United States. Contraception. 2008; 79(1):5-14. PMC: 3638200. DOI: 10.1016/j.contraception.2008.08.003. View

11.

Jareid M, Thalabard J, Aarflot M, Bovelstad H, Lund E, Braaten T . Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecol Oncol. 2018; 149(1):127-132. DOI: 10.1016/j.ygyno.2018.02.006. View

12.

Ness R, Dodge R, Edwards R, Baker J, Moysich K . Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer. Ann Epidemiol. 2010; 21(3):188-96. PMC: 3052991. DOI: 10.1016/j.annepidem.2010.10.002. View

13.

Franceschi C, Campisi J . Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014; 69 Suppl 1:S4-9. DOI: 10.1093/gerona/glu057. View

14.

. Committee Opinion No. 642: Increasing Access to Contraceptive Implants and Intrauterine Devices to Reduce Unintended Pregnancy. Obstet Gynecol. 2015; 126(4):e44-e48. DOI: 10.1097/AOG.0000000000001106. View

15.

Gnagy S, Ming E, Devesa S, Hartge P, Whittemore A . Declining ovarian cancer rates in U.S. women in relation to parity and oral contraceptive use. Epidemiology. 2000; 11(2):102-5. DOI: 10.1097/00001648-200003000-00004. View

16.

Wheeler L, Desanto K, Teal S, Sheeder J, Guntupalli S . Intrauterine Device Use and Ovarian Cancer Risk: A Systematic Review and Meta-analysis. Obstet Gynecol. 2019; 134(4):791-800. DOI: 10.1097/AOG.0000000000003463. View

17.

Poole E, Merritt M, Jordan S, Yang H, Hankinson S, Park Y . Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness. Cancer Epidemiol Biomarkers Prev. 2013; 22(3):429-37. PMC: 3596470. DOI: 10.1158/1055-9965.EPI-12-1183-T. View

18.

Titus-Ernstoff L, Perez K, Cramer D, Harlow B, Baron J, Greenberg E . Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer. 2001; 84(5):714-21. PMC: 2363792. DOI: 10.1054/bjoc.2000.1596. View

19.

Barnard M, Poole E, Curhan G, Eliassen A, Rosner B, Terry K . Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses' Health Studies. JAMA Oncol. 2018; 4(12):1675-1682. PMC: 6400245. DOI: 10.1001/jamaoncol.2018.4149. View

20.

Fali T, Vallet H, Sauce D . Impact of stress on aged immune system compartments: Overview from fundamental to clinical data. Exp Gerontol. 2018; 105:19-26. DOI: 10.1016/j.exger.2018.02.007. View